Carillon®
Mitral Contour System



A Breakthrough Percutaneous Approach to Treat Functional Mitral Regurgitation

Cardiac Dimensions®
Reshaping the Course of Heart Failure™

SIMPLICITY

Easy Access & Deployment



- Rapid device deployment via 9F catheter.
- Designed to re-shape mitral annulus, reducing dilation and MR.
- Completely right-sided procedure (no trans-septal puncture required).

Re-capture Capability



- Unique delivery catheter can re-compress device and re-capture it for patient safety.
- Re-capture feature allows for a new device to be deployed and optimize device position.

SOPHISTICATION

Anchor Architecture



- Architecture allows for incorporation into the coronary sinus.
- Designed for long-term durability.
- Preserves future treatment options (e.g., LV lead, surgical mitral repair).

Accommodates Variable Anatomy



- Different sizes, lengths and patient-specific device placement accommodate variable anatomy.
- Efficacy can be confirmed real-time peri-operatively.

Carillon®: Compelling Clinical Experience

The landmark TITAN trial evaluated Carillon in a representative functional mitral regurgitation population with a comparison group.

Demographics[1]

	Implanted Patients (n=36)	Comparison Group (n=17)
Age (yrs)	62.4	62.6
Ischemic	66%	53%
EF	28.7%	27.0%
LVEDD (mm)	66.3	67.2
NYHA Class II	0%	6%
NYHA Class III	94%	94%
NYHA Class IV	6%	0%
MR Grade 2+	19%	12%
MR Grade 3+	56%	59%
MR Grade 4+	25%	29%

Safety Outcomes[1]

		1 Month MAE incidence*	
		Rate	Device-Related
Event	Death	1.9%	0%
	MI	0%	0%
	Cardiac Perforation	0%	0%
	Device Embolization	0%	0%
	Surgery or PCI Related to Device	0%	0%
	Total MAE Rate	1.90%	0%

*Intent-to-Treat

Reduction in Mitral Regurgitation[1]



Intragroup comparisons of echocardiographic data from baseline through 12 months were assessed using a paired t-test.

Carillon®: Compelling Clinical Experience

Reverse Remodeling[1]

LV End Diastolic Diameter



LV End Systolic Diameter



LV End Diastolic Volume



LV End Systolic Volume



Implanted Comparison Group

Two Year Clinical Efficacy[2]

6 Minute Walk Test



n=15 @24 months

NYHA Class



n=19 @24 months

1. Hoppe UC, Siminiak T, Haude M, et.al., European Heart Journal 2010;31:160-161.
2. Reuter DG Presentation. Oct. 2011 PCR London Valves.